Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review

Area of Science:

• Molecular Biology
• Oncology
• Medicinal Chemistry

Background:

• S-phase kinase-associated protein 2 (Skp2) functions as a key component of SCF^Skp2 E3 ubiquitin ligases.
• Skp2 is recognized as a significant oncogene, driving cancer progression and making it a critical target for anticancer research.
• The structural elucidation of Skp2 has paved the way for the development of targeted inhibitory compounds.

Purpose of the Study:

• To provide a comprehensive overview of the structural characteristics of Skp2.
• To elucidate the ubiquitination function mediated by the SCF^Skp2 complex.
• To summarize and analyze existing natural and synthetic compounds that inhibit Skp2 activity.

Main Methods:

• Literature review of structural biology studies on Skp2.
• Analysis of the ubiquitination pathways involving Skp2.
• Compilation and comparison of reported Skp2 inhibitors, including their efficacy data (IC50 values).

Main Results:

• Detailed description of Skp2's structural features relevant to its function.
• Explanation of how SCF^Skp2 targets proteins for ubiquitination and degradation.
• A catalog of diverse Skp2 inhibitors, both natural and synthetic, with associated cellular IC50 data across various tumor types.

Conclusions:

• Skp2 inhibitors show promise in preclinical cancer models, with varying efficacy.
• The effectiveness of Skp2-targeted therapy is contingent upon specific cancer types, disease stages, and underlying pathological mechanisms.
• Personalized approaches considering tumor-specific factors are crucial for optimizing Skp2 inhibitor selection in cancer treatment.